Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

Open Access

Peer-reviewed

Research Article

Alberto Ferreira ,

* E-mail: alberto.ferreira@novartis.com

Affiliation Novartis Pharma AG, Basel, Switzerland
⨯
Alexandros Sagkriotis,

Affiliation Novartis Pharma AG, Basel, Switzerland
⨯
Melvin Olson,

Affiliation Novartis Pharma AG, Basel, Switzerland
⨯
Jingsong Lu,

Affiliation IMS Health, Plymouth Meeting, PA, United States of America
⨯
Charles Makin,

Affiliation IMS Health, Plymouth Meeting, PA, United States of America
⨯
Fran Milnes

Affiliation Novartis Pharma AG, Basel, Switzerland
⨯

Reader Comments (0)

Macular degeneration
Is the Subject Area "Macular degeneration" applicable to this article?

Thanks for your feedback.
Physicians
Is the Subject Area "Physicians" applicable to this article?

Thanks for your feedback.
Eyes
Is the Subject Area "Eyes" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Vision
Is the Subject Area "Vision" applicable to this article?

Thanks for your feedback.
Growth factors
Is the Subject Area "Growth factors" applicable to this article?

Thanks for your feedback.
Data management
Is the Subject Area "Data management" applicable to this article?

Thanks for your feedback.
Health economics
Is the Subject Area "Health economics" applicable to this article?

Thanks for your feedback.